Literature DB >> 11152104

Posttransplant bone disease: evidence for a high bone resorption state.

A V Cayco1, J Wysolmerski, C Simpson, M A Mitnick, C Gundberg, A Kliger, M Lorber, D Silver, G Basadonna, A Friedman, K Insogna, D Cruz, M Bia.   

Abstract

Loss of bone is a significant problem after renal transplant. Although bone loss in the first post transplant year has been well documented, conflicting data exist concerning bone loss after this time. It is equally unclear whether bone loss in long-term renal transplant recipients correlates with bone turnover as it does in postmenapausal osteoporosis. To examine these issues, we conducted a cross-sectional study to define the prevalence of osteoporosis in long-term (> 1 year) renal transplant recipients with preserved renal function (mean creatinine clearance 73 +/- 23 ml/min). Bone mineral density (BMD) was measured at the hip, spine and wrist by DEXA in 69 patients. Markers for bone formation (serum osteocalcin) and bone resorption [urinary levels of pyridinoline (PYD) and deoxypyridinoline (DPD)] were also measured as well as parameters of calcium metabolism. Correlations were made between these parameters and BMD at the various sites. The mean age of the patients was 45 +/- 11 years. Eighty eight percent of patients were on cyclosporine (12% on tacrolimus) and all but 2 were on prednisone [mean dose 9 +/- 2 mg/day)]. Osteoporosis (BMD more than 2.5 SD below peak adult BMD) at the spine or hip was diagnosed in 44% of patients and osteopenia was present in an additional 44%. Elevated levels of intact parathyroid hormone (i PTH) were observed in 81% of patients. Elevated urinary levels of PYD or DPD were present in 73% of patients and 38% had elevated serum levels of osteocalcin. Levels of calcium, and of 25(OH) and 1,25(OH)2 vitamin D were normal. In a stepwise multiple regression model that included osteocalcin, PYD, DPD, intact PTH, age, years posttransplant, duration of dialysis, cumulative prednisone dose, smoking, and diabetes: urinary PYD was the strongest predictor of bone mass. These results demonstrate that osteoporosis is common in long-term renal transplant recipients. The data also suggest that elevated rates of bone resorption contribute importantly to this process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11152104     DOI: 10.1097/00007890-200012270-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  14 in total

Review 1.  Assessment of bone mass following renal transplantation in children.

Authors:  Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

2.  Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism.

Authors:  M E Cho; Z Duan; C E Chamberlain; J C Reynolds; M S Ring; R B Mannon
Journal:  Transplant Proc       Date:  2010-11       Impact factor: 1.066

3.  Renal phosphate loss in long-term kidney transplantation.

Authors:  Supinda Sirilak; Kamonwan Chatsrisak; Atiporn Ingsathit; Surasak Kantachuvesiri; Vasant Sumethkul; Wasana Stitchantrakul; Piyanuch Radinahamed; Sinee Disthabanchong
Journal:  Clin J Am Soc Nephrol       Date:  2011-12-01       Impact factor: 8.237

Review 4.  Osteoporosis in patients with diabetes after kidney transplantation.

Authors:  Elvira O Gosmanova; Aidar R Gosmanov
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

5.  Bone mineral density in live related kidney transplant children and adolescents.

Authors:  Amr A el-Husseini; Amgad E el-Agroudy; Ehab W Wafa; Tarek Mohsen; Mohamed A Sobh; Mohamed A Ghoneim
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

6.  Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism.

Authors:  Simon D Roe; Christine J Porter; Ian M Godber; David J Hosking; Michael J Cassidy
Journal:  Osteoporos Int       Date:  2004-07-16       Impact factor: 4.507

7.  Long-term fracture risk following renal transplantation: a population-based study.

Authors:  Line M Vautour; L Joseph Melton; Bart L Clarke; Sara J Achenbach; Ann L Oberg; James T McCarthy
Journal:  Osteoporos Int       Date:  2003-12-09       Impact factor: 4.507

8.  Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease.

Authors:  Sakura Yamamoto; Atsushi Suzuki; Hitomi Sasaki; Sahoko Sekiguchi-Ueda; Shogo Asano; Megumi Shibata; Nobuki Hayakawa; Shuji Hashimoto; Kiyotaka Hoshinaga; Mitsuyasu Itoh
Journal:  J Bone Miner Metab       Date:  2012-10-18       Impact factor: 2.626

9.  Musculoskeletal affections among kidney recipients: prevalence and risk predictors.

Authors:  Alia M Atallah; Seif M Farag; Mohamed K Senna; Mohamed A Ghoneim
Journal:  Rheumatol Int       Date:  2008-04-29       Impact factor: 2.631

Review 10.  Osteoporosis after solid organ and bone marrow transplantation.

Authors:  Adi Cohen; Elizabeth Shane
Journal:  Osteoporos Int       Date:  2003-08-08       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.